EA032287B1 - Терапия глатирамером ацетатом с низкой кратностью - Google Patents

Терапия глатирамером ацетатом с низкой кратностью Download PDF

Info

Publication number
EA032287B1
EA032287B1 EA201691347A EA201691347A EA032287B1 EA 032287 B1 EA032287 B1 EA 032287B1 EA 201691347 A EA201691347 A EA 201691347A EA 201691347 A EA201691347 A EA 201691347A EA 032287 B1 EA032287 B1 EA 032287B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dose
treatment
multiple sclerosis
subcutaneously
months
Prior art date
Application number
EA201691347A
Other languages
English (en)
Russian (ru)
Other versions
EA201691347A3 (ru
EA201691347A2 (ru
Inventor
Эти Клингер
Original Assignee
Йеда Рисерч Энд Дивелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43605835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032287(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Йеда Рисерч Энд Дивелопмент Ко. Лтд. filed Critical Йеда Рисерч Энд Дивелопмент Ко. Лтд.
Publication of EA201691347A2 publication Critical patent/EA201691347A2/ru
Publication of EA201691347A3 publication Critical patent/EA201691347A3/ru
Publication of EA032287B1 publication Critical patent/EA032287B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
EA201691347A 2009-08-20 2010-08-19 Терапия глатирамером ацетатом с низкой кратностью EA032287B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27468709P 2009-08-20 2009-08-20
US33761210P 2010-02-11 2010-02-11

Publications (3)

Publication Number Publication Date
EA201691347A2 EA201691347A2 (ru) 2016-10-31
EA201691347A3 EA201691347A3 (ru) 2016-11-30
EA032287B1 true EA032287B1 (ru) 2019-05-31

Family

ID=43605835

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201691347A EA032287B1 (ru) 2009-08-20 2010-08-19 Терапия глатирамером ацетатом с низкой кратностью
EA201270292A EA019998B9 (ru) 2009-08-20 2010-08-19 Терапия глатирамером ацетатом с низкой кратностью
EA201400394A EA032283B1 (ru) 2009-08-20 2010-08-19 Терапия глатирамером ацетатом с низкой кратностью

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201270292A EA019998B9 (ru) 2009-08-20 2010-08-19 Терапия глатирамером ацетатом с низкой кратностью
EA201400394A EA032283B1 (ru) 2009-08-20 2010-08-19 Терапия глатирамером ацетатом с низкой кратностью

Country Status (34)

Country Link
US (15) US8399413B2 (enExample)
EP (5) EP2630962B1 (enExample)
JP (3) JP6038653B2 (enExample)
KR (4) KR20140061559A (enExample)
CN (3) CN105770855A (enExample)
AR (2) AR077896A1 (enExample)
AT (1) AT15421U1 (enExample)
AU (1) AU2010284666B2 (enExample)
BR (1) BR112012003730A2 (enExample)
CA (2) CA2760802C (enExample)
CY (2) CY1114537T1 (enExample)
CZ (2) CZ29723U1 (enExample)
DE (1) DE202010018377U1 (enExample)
DK (5) DK2405749T3 (enExample)
EA (3) EA032287B1 (enExample)
ES (4) ES2424692T3 (enExample)
HK (2) HK1258008A1 (enExample)
HR (4) HRP20130677T1 (enExample)
HU (2) HUE031282T2 (enExample)
IL (3) IL218106A0 (enExample)
LT (3) LT2630962T (enExample)
ME (2) ME02662B (enExample)
MX (1) MX2012002082A (enExample)
NZ (1) NZ598661A (enExample)
PL (4) PL2949335T3 (enExample)
PT (4) PT2405749E (enExample)
RS (2) RS52885B (enExample)
SG (2) SG178495A1 (enExample)
SI (4) SI2949335T1 (enExample)
SK (1) SK501352015U1 (enExample)
SM (2) SMT201700057T1 (enExample)
TW (3) TWI477273B (enExample)
UA (1) UA103699C2 (enExample)
WO (1) WO2011022063A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8077333B2 (en) * 2002-09-09 2011-12-13 Canon Kabushiki Kaisha Printing control apparatus and printing control method
DK2405749T3 (da) 2009-08-20 2013-07-15 Yeda Res & Dev Lavfrekvent glatiramer-acetat-terapi
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
AU2011313842B2 (en) 2010-10-11 2016-12-15 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
BR112014008752A2 (pt) 2011-10-10 2017-04-25 Teva Pharma polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
BR112015016169A2 (pt) * 2013-01-04 2017-07-11 Teva Pharma caracterizando produtos de drogas relacionados a acetato de glatirâmero
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN103641897B (zh) * 2013-11-27 2017-01-04 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
CN104844697B (zh) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107550853B (zh) * 2016-06-30 2020-06-12 深圳翰宇药业股份有限公司 一种醋酸格拉替雷注射液的制备方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
LT3506921T (lt) 2016-08-31 2023-08-10 Mapi Pharma Ltd Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
KR102519053B1 (ko) 2021-02-08 2023-04-06 건국대학교 산학협력단 염산가스의 농도 측정을 위한 수분 전처리 시스템
KR102519054B1 (ko) 2021-03-12 2023-04-06 건국대학교 산학협력단 나피온 드라이어와 수분 전처리장치의 결합시스템
WO2023061935A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
WO2023062511A1 (en) * 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070173442A1 (en) * 2003-05-14 2007-07-26 Timothy Vollmer Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple schlerosis
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
EP0219899B1 (en) 1985-10-11 1990-08-08 Duphar International Research B.V Automatic injector
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HU229719B1 (en) 1998-09-25 2014-05-28 Yeda Res & Dev Copolymer-1-delated polipeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
CA2355400A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
HK1048260B (zh) 1999-08-27 2009-03-13 杰南技术公司 用於抗erbb2抗体治疗的制剂
ES2243450T3 (es) 2000-01-20 2005-12-01 Yeda Research And Development Co. Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
WO2001060392A1 (en) 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL153236A0 (en) 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
MXPA02007109A (es) 2000-06-07 2002-12-13 Yeda Res & Dev El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para proteger a las celulas del sistema nervioso central de la toxicidad del glutamato.
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
EP1565486A2 (en) 2002-11-13 2005-08-24 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CN100464796C (zh) 2002-11-25 2009-03-04 特克法马许可公司 包括可复位安全释放设备的自动注射器
US7274347B2 (en) 2003-06-27 2007-09-25 Texas Instruments Incorporated Prevention of charge accumulation in micromirror devices through bias inversion
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
CA2518079A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
UA89226C2 (en) * 2004-03-25 2010-01-11 Янссен Фармацевтика Н.В. Imidazole compounds
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
WO2005120542A2 (en) 2004-05-07 2005-12-22 Peptimmune, Inc. Methods of treating disease with random copolymers
KR101347562B1 (ko) * 2004-06-25 2014-01-03 더 브리검 앤드 우먼즈 하스피털, 인크. 신경계 장애의 치료를 위한 조성물 및 방법
US20090048181A1 (en) * 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DE602005018800D1 (de) 2004-09-09 2010-02-25 Teva Pharma Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
CA2583589C (en) 2004-10-29 2012-04-24 Sandoz Ag Processes for preparing glatiramer
RU2419638C2 (ru) 2005-02-02 2011-05-27 Тева Фармасьютикал Индастриз, Лтд. Способ получения полипептидных смесей с использованием гидрогенолиза
RS52867B (sr) 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
SG173339A1 (en) 2006-06-30 2011-08-29 Abbott Biotech Ltd Automatic injection device
ATE452140T1 (de) 2006-07-05 2010-01-15 Momenta Pharmaceuticals Inc Verbessertes verfahren zur herstellung von copolymer-1
US20110123482A1 (en) * 2007-10-01 2011-05-26 The Johns Hopkins University Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide
CN101877963A (zh) 2007-11-28 2010-11-03 泰华制药工业有限公司 延缓临床确诊的多发性硬化症发作的方法
DK2275086T3 (da) 2009-07-15 2012-07-09 Teva Pharma Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
DK2405749T3 (da) 2009-08-20 2013-07-15 Yeda Res & Dev Lavfrekvent glatiramer-acetat-terapi
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
AU2011313842B2 (en) 2010-10-11 2016-12-15 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
BR112014008752A2 (pt) 2011-10-10 2017-04-25 Teva Pharma polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
BR112015016169A2 (pt) 2013-01-04 2017-07-11 Teva Pharma caracterizando produtos de drogas relacionados a acetato de glatirâmero
CN105188751A (zh) 2013-03-12 2015-12-23 泰华制药工业有限公司 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173442A1 (en) * 2003-05-14 2007-07-26 Timothy Vollmer Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple schlerosis
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis

Also Published As

Publication number Publication date
US20190054013A1 (en) 2019-02-21
HK1258008A1 (en) 2019-11-01
TW201733575A (zh) 2017-10-01
US20180311149A1 (en) 2018-11-01
KR20120090044A (ko) 2012-08-16
EP2949335A1 (en) 2015-12-02
DK2630962T3 (en) 2018-07-23
DK2949335T3 (en) 2017-07-31
ES2424692T3 (es) 2013-10-07
US20120071416A1 (en) 2012-03-22
NZ598661A (en) 2013-02-22
PT2630962T (pt) 2018-08-01
RS55607B1 (sr) 2017-06-30
SI2949335T1 (sl) 2017-05-31
EP2949335B1 (en) 2017-01-04
HUE039335T2 (hu) 2018-12-28
EP2630962A1 (en) 2013-08-28
PL2949335T3 (pl) 2017-07-31
US20180185274A1 (en) 2018-07-05
JP2015187125A (ja) 2015-10-29
CY1114537T1 (el) 2016-10-05
AU2010284666B2 (en) 2012-12-06
EP3199172A8 (en) 2017-10-11
US8969302B2 (en) 2015-03-03
EA032283B1 (ru) 2019-05-31
HRP20130677T1 (en) 2013-10-11
EA201400394A1 (ru) 2014-10-30
WO2011022063A1 (en) 2011-02-24
CZ30474U1 (cs) 2017-03-14
US20150164977A1 (en) 2015-06-18
ME01536B (me) 2014-04-20
US8399413B2 (en) 2013-03-19
US20160250251A1 (en) 2016-09-01
KR20160038057A (ko) 2016-04-06
IL233468A0 (en) 2014-08-31
CA2760802A1 (en) 2011-02-24
AU2010284666A1 (en) 2011-09-22
EA201691347A3 (ru) 2016-11-30
US20170196803A1 (en) 2017-07-13
EP2405749B1 (en) 2013-05-08
SI3199172T1 (sl) 2018-10-30
EP3409286B1 (en) 2020-08-12
PT3199172T (pt) 2018-10-18
ES2688873T3 (es) 2018-11-07
US20150202247A1 (en) 2015-07-23
TW201521718A (zh) 2015-06-16
MX2012002082A (es) 2012-08-23
SG178495A1 (en) 2012-03-29
BR112012003730A2 (pt) 2020-07-21
US9155776B2 (en) 2015-10-13
IL218106A0 (en) 2012-04-30
EA019998B1 (ru) 2014-07-30
JP6169644B2 (ja) 2017-07-26
AR099078A2 (es) 2016-06-29
HK1225310A1 (zh) 2017-09-08
US20110046065A1 (en) 2011-02-24
PT2949335T (pt) 2017-02-03
CY1118529T1 (el) 2017-07-12
SG10201405806SA (en) 2014-11-27
CA2760802C (en) 2016-01-12
TWI643614B (zh) 2018-12-11
SI2405749T1 (sl) 2013-10-30
AT15421U1 (de) 2017-08-15
LT2630962T (lt) 2018-10-25
DK2405749T3 (da) 2013-07-15
EP2630962B1 (en) 2018-06-27
HRP20181254T1 (hr) 2019-01-25
EA201691347A2 (ru) 2016-10-31
DK201600003U1 (da) 2016-01-22
US20170095523A1 (en) 2017-04-06
KR20170123354A (ko) 2017-11-07
LT2949335T (lt) 2017-03-27
SK501352015U1 (sk) 2017-07-03
EP3199172B1 (en) 2018-07-11
SI2630962T1 (sl) 2018-10-30
JP2017132773A (ja) 2017-08-03
JP6038653B2 (ja) 2016-12-07
EP2405749A1 (en) 2012-01-18
PT2405749E (pt) 2013-07-22
US20180064639A1 (en) 2018-03-08
EA201270292A1 (ru) 2012-12-28
CN102625657A (zh) 2012-08-01
HRP20181253T1 (hr) 2018-11-02
US20150250845A1 (en) 2015-09-10
HRP20170056T2 (hr) 2017-12-15
CN105770855A (zh) 2016-07-20
US20130165387A1 (en) 2013-06-27
LT3199172T (lt) 2018-10-25
PL2405749T3 (pl) 2013-12-31
US8232250B2 (en) 2012-07-31
US20170296464A1 (en) 2017-10-19
EP2405749A4 (en) 2012-08-22
HUE031282T2 (hu) 2017-06-28
CZ29723U1 (cs) 2016-08-30
DK3199172T3 (en) 2018-10-08
EP3409286A1 (en) 2018-12-05
US9402874B2 (en) 2016-08-02
EA019998B9 (ru) 2016-01-29
CA2760802F (en) 2011-02-24
EP3199172A1 (en) 2017-08-02
PL2630962T3 (pl) 2018-12-31
AR077896A1 (es) 2011-09-28
UA103699C2 (ru) 2013-11-11
SMT201700057B (it) 2017-03-08
DE202010018377U1 (de) 2016-02-25
ES2612001T4 (es) 2018-02-07
PL3199172T3 (pl) 2019-01-31
JP2013502415A (ja) 2013-01-24
RS52885B (sr) 2014-02-28
DK201600003Y3 (da) 2016-02-12
CA2876966A1 (en) 2011-02-24
ME02662B (me) 2017-06-20
CN107050423A (zh) 2017-08-18
TWI477273B (zh) 2015-03-21
TW201119645A (en) 2011-06-16
KR20140061559A (ko) 2014-05-21
ES2689711T3 (es) 2018-11-15
SMT201700057T1 (it) 2017-03-08
IL251943A0 (en) 2017-06-29
HK1165959A1 (en) 2012-10-19
US20190175494A1 (en) 2019-06-13
HRP20170056T1 (hr) 2017-03-24
HK1218250A1 (en) 2017-02-10
ES2612001T3 (es) 2017-05-11

Similar Documents

Publication Publication Date Title
EA032287B1 (ru) Терапия глатирамером ацетатом с низкой кратностью
HK1234325B (en) Dosing regimen for multiple sclerosis
HK1165959B (en) Low frequency glatiramer acetate therapy
HK1188722B (en) Low frequency glatiramer acetate therapy

Legal Events

Date Code Title Description
QB4A Registration of a licence in a contracting state